



DATE	STOCK	RECOMD	ENTRY PRICE	TARGET	STOP LOSS
27.12.2021	AUROPHARMA	BUY	708	730	690
27.12.2021	HCLTECH	BUY	1265	1310	1225
27.12.2021	GODREJCP	BUY	965	1005	940

NOTE –These Stocks are recommended only for short term investment (Stop Loss should be followed Daily closing basis).

**TECHNICAL OUTLOOK**

NIFTY WEEKLY CLOSE – 17003.75 (↑18.55)

Last week, Nifty began with a gap-down at 16824 and breaching this support, it moved lower till 16410. At this level, Nifty saw buying support and moved higher to cross 17000, however, faced resistance near 17150. Nifty closed at 17003 with a minor gain of 18 points.

Nifty is placed below its 13-day, 55-day and 13-week EMA. It is placed above all other averages. Daily RSI has moved above average but weekly RSI is placed below its average.

Going ahead 17200-17300 would be the resistance zone for Nifty. On the other hand, 16400 would be the immediate support. 16300 which is near the 200-day EMA, is an important support level for Nifty.



**WEEKLY INVESTMENT IDEAS REVIEW**

DATE	STOCK	RECOMD	ENTRY PRICE	TARGET	STOP LOSS	TODAY CLOSE	NET CHANGE (%)	REMARK
20.12.2021	JSL	BUY	188	215	175	183.3	-2.56	Exit (High 188)
20.12.2021	POWERGRID	BUY	209	230	198	205.4	-1.75	Stop loss hit
20.12.2021	WIPRO	BUY	670	710	650	698.45	4.07	Exit (High 702)

**WEEKLY MARKET REVIEW****Nifty closes above 17,000 level amid volatility**

The benchmark indices saw high volatility during the week as the impact of Omicron variant continued to puzzle investors. The Nifty settled above the key 17,000 level. Investors have been juggling with the news of the rapid spread of the omicron variant and the introduction of containment measures by governments around the world, with new scientific analysis of its severity and pharmaceutical developments on booster shots and treatments.

In the week ended on Friday, 24 December 2021, the Sensex rose 112.57 points or 0.20% to settle at 57,124.31. The Nifty 50 index gained 18.55 points or 0.11% to settle at 17,003.75. The BSE Mid-Cap index fell 184.88 or 0.75% to settle at 24,357.27. The BSE Small-Cap index shed 88.65 points or 0.31% to settle at 28,366.55.

Drug major Cipla jumped 5.56%. The drug major has received final approval for its Lanreotide injection, from the USFDA. It is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).

UltraTech Cement slipped 1.52%. The cement maker said that it has commenced operations from its bulk terminal at Kalamboli, Navi Mumbai. With a capacity to handle 1.2 MTPA cement and considering the large infrastructure development projects in and around Mumbai, the bulk terminal will strengthen the company further to increase its sales of bulk cement.

Indian Oil Corporation (IOCL) declined 2.35%. The PSU OMC will acquire 36,93,750 equity shares, equivalent to 4.93% stake of Indian Gas Exchange (IGX), a subsidiary of Indian Energy Exchange (IEX). As per the company's press statement, the acquisition of equity stake in IGX will provide an opportunity for IOCL to become part of India's natural gas market and increase its presence to achieve leadership position in the

market. Separately, IOCL announced the approval for an investment proposal of new crude oil pipeline system with nameplate capacity of 17.5 million metric tonnes per annum (MMTPA) from Mundra (Gujarat) to Panipat (Haryana) alongwith with augmentation of crude oil tank farm at Mundra, at an estimated cost of Rs 9,028 crore. The project will meet the enhanced crude oil requirement arising out of capacity expansion of Panipat Refinery to 25 MMTPA from 15 MMTPA. The project is expected to be completed within 36 months (3 years) and would be synchronized with the commissioning of Panipat Refinery expansion project.

Larsen & Toubro (L&T) rose 0.68%. The company's construction arm secured a 'significant' order for its buildings and factories business from a reputed developer. According L&T's classification, the value of 'significant' contracts lies between Rs 1,000 crore to Rs 2,500 crore.

Kotak Mahindra Bank shed 2.57%. Kotak Mahindra Prime (Kotak Prime), a subsidiary of Kotak Mahindra Bank, announced that it has acquired the passenger vehicle finance portfolio of Ford Credit India Private Limited (FCIPL), the Indian captive financing arm of Ford Motor Company. FCIPL has been operating in India since 2015.

Meanwhile, India reported 6,650 new COVID-19 cases and 374 deaths in the last 24 hours. The country's active caseload currently stands at 77,516. Meanwhile, India's Omicron tally jumped to 358 with 88 cases in Maharashtra and 67 in Delhi. In the US, President Joe Biden said in a Tuesday address that people with booster shots are "highly protected," urging Americans to get their extra doses. The rapid spread of the Omicron COVID-19 variant triggered stricter containment measures across Europe.

Source: [www.capitalmarket.com](http://www.capitalmarket.com)



### SAJAG SECURITIES PVT. LTD.

MEMBER: NATIONAL STOCK EXCHANGE OF INDIA LTD.

MEMBER: BOMBAY STOCK EXCHANGE LTD.

DEPOSITORY PARTICIPANT: NATIONAL SECURITIES DEPOSITORY LTD.

DEPOSITORY PARTICIPANT: CENTRAL DEPOSITORY SERVICES LTD.

33/15 - B, KARVE ROAD, REGENT CHAMBERS, PUNE - 411004, TEL: 91-20-66014737, FAX: 91-20-25302555

email: [business@sajag.co.in](mailto:business@sajag.co.in) / [investorgrievance@sajag.co.in](mailto:investorgrievance@sajag.co.in)

NSE TM ID - 07549

BSE TM ID - 3105

NSDL DP ID: IN303647

CDSL DP ID: 12062400

SEBI Regn. No. INZ000221337

**Disclosure:** This report is issued by Sajag Securities Pvt. Ltd. (SSPL), a stock broking company, which is regulated by SEBI and its research activities are as per SEBI Guidelines for Research Analysts December 2014. Registration Number: INH000001923. This report is prepared and distributed by SSPL for information purpose only. SSPL and the research analyst(s) who prepared this report do not have any long or short positions in derivatives markets in any of the above mentioned securities. SSPL or the research analyst(s) do not have ownership of 1% or more in the company. The research analyst(s) who prepared this research report hereby certifies that the views expressed in this research report accurately reflect the research analyst's personal views about all of the subject issuers and/or securities, that the analyst(s) have no known material conflict of interest and no part of the research analyst's compensation was, is or will be, directly or indirectly, related to the specific views or recommendations contained in this research report.

**Disclaimer:** Neither the information contained herein nor any opinion expressed should be construed or deemed to be construed as solicitation or as offering advice for the purposes of the purchase or sale of any security or investment or derivatives. The information and opinions contained in the report were considered by SSPL to be valid when published. The report also contains information provided to SSPL by third parties. The source of such information will usually be disclosed in the report. While SSPL has taken all responsible steps to ensure that this information is correct, SSPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his/her own risk and SSPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily a guide to future performance. The report does not have regard to the specific investment objective, financial situation and the particular needs of any specific person who may receive this report. Investor must undertake independent analysis with their own legal, tax and financial advisors and reach their own decision regarding the appropriateness of investing in any securities or investment strategies discussed and recommended in this report and should understand that statements regarding future prospects may not be realized. In no circumstances be it used or considered as an offer to sell or a solicitation of any offer to buy or sell the securities mentioned in it. The information contained in the research reports may have been taken from trade and statistical services and other sources, which we believe reliable. SSPL does not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice. The target prices mentioned in the report are based on certain assumptions as of the date appearing in the material and may be subject to change from time to time without notice.